Tremfya Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of psoriasis and psoriatic arthritis, clinical success of biologic therapies, expansion of specialty dermatology care, improved patient adherence to biologics, wider reimbursement coverage for biologic drugs.

The growth in the forecast period can be attributed to increasing demand for long-term inflammatory disease management, expansion of biologics into gastroenterology indications, rising preference for less frequent dosing regimens, growing investments in monoclonal antibody therapies, increasing focus on personalized immunology treatments. Major trends in the forecast period include increasing adoption of il-23 inhibitor therapies, growing demand for long-interval biologic treatments, expansion of autoimmune disease indications, rising use of subcutaneous biologic injections, enhanced focus on targeted immunomodulation.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Tremfya market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own cells, tissues, or organs, treating them as foreign invaders. The increasing prevalence of these conditions is influenced by genetic predisposition, environmental triggers, lifestyle changes, greater awareness, and improved diagnostic capabilities. Tremfya, a monoclonal antibody targeting interleukin-23 (IL-23), helps manage autoimmune diseases by regulating the immune system’s overactive response, reducing inflammation, and alleviating symptoms in conditions such as psoriasis and psoriatic arthritis. For example, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, approximately 212,136 males and 362,137 females were projected to have rheumatoid arthritis (RA) in 2025, with the numbers expected to rise by 2040 to about 280,040 males and 479,828 females. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the Tremfya market.

The increasing healthcare expenditure is expected to support the growth of the Tremfya market. Healthcare expenditure encompasses total spending on medical services, products, and public health initiatives to maintain and improve health. The growth in healthcare spending is driven by an aging population requiring more medical care and the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions. Higher healthcare expenditure improves access to advanced biologic therapies like Tremfya by expanding reimbursement coverage, increasing diagnosis rates, and enhancing patient affordability. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency administering Medicare and Medicaid programs, U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or roughly $14,570 per individual. Therefore, increasing healthcare expenditure is driving the growth of the Tremfya market.

Key players in the Tremfya market are securing regulatory approvals to expand its treatment indications, such as for moderate-to-severe Crohn’s disease, thereby broadening its patient base and market potential. Regulatory approvals are official authorizations granted by agencies like the FDA or EMA, allowing a drug to be marketed for specific uses after demonstrating safety, efficacy, and quality. For example, in September 2024, Johnson & Johnson, a US-based pharmaceutical company, received FDA approval for TREMFYA (guselkumab) for adults with moderately to severely active ulcerative colitis, marking it as the first dual-acting interleukin-23 inhibitor approved for this condition. This approval followed positive results from the Phase 2b/3 QUASAR study, in which approximately 50% of patients achieved clinical remission after 44 weeks of treatment. TREMFYA targets interleukin-23, helping normalize the inflammatory response in the colon.

Major companies operating in the tremfya market are Johnson & Johnson.

North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tremfya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the tremfya market by increasing costs of imported monoclonal antibody raw materials, bioreactor components, sterile filling systems, and cold-chain logistics used in biologic drug manufacturing. North America and Europe are most affected due to reliance on globally sourced biologic inputs, while Asia-Pacific faces export cost pressures for finished injectable biologics. These tariffs are contributing to higher manufacturing and distribution expenses. At the same time, they are supporting domestic biologics production, regional manufacturing expansion, and strengthened supply chains for immunology-focused therapies.

The tremfya market research report is one of a series of new reports that provides tremfya market statistics, including tremfya industry global market size, regional shares, competitors with a tremfya market share, detailed tremfya market segments, market trends and opportunities, and any further data you may need to thrive in the tremfya industry. This tremfya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tremfya (guselkumab) is a biologic therapy used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by inhibiting interleukin-23 (IL-23), a protein that plays a key role in the inflammatory processes of these conditions. Tremfya is administered via subcutaneous injection once every eight weeks following initial loading doses.

The primary indications for Tremfya include moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). Moderate-to-severe plaque psoriasis is a chronic skin disorder marked by red, inflamed patches covered with silvery scales. Tremfya is available in formulations such as subcutaneous injections and intravenous infusions and is distributed through hospital and retail pharmacies. It serves end users including adult and geriatric patients.

The tremfya market consists of sales of subcutaneous injection pens, pre-filled syringes, and vials for healthcare providers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.